← Back to Clinical Trials
Recruiting NCT04828954

NCT04828954 Variable Immobilization Protocol for Arthroplasty of the Carpometacarpal Joint of the Thumb

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04828954
Status Recruiting
Phase
Sponsor University of Chicago
Condition Thumb Osteoarthritis
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2021-04-19
Primary Completion 2027-05-04

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Immobilization for 2-weeks postoperativeImmobilization for 6-weeks postoperative

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2021-04-19 with a primary completion date of 2027-05-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Thumb carpometacarpal (CMC) osteoarthritis (OA) is common, seen frequently in middle-aged and elderly women. While a variety of surgical treatments have been described with none superior to any other, there is no consensus on the optimal duration of postoperative immobilization. Immobilization following surgery is critical for wound healing, pain control, and aid with activities of daily living in the early recovery period, though the duration of this must be weighed against the negative impacts of immobilization, such as stiffness, contracture, and delay in return to full function. The information gained in this study may allow hand surgeons to use an evidence-based postoperative rehabilitation protocol. Thus, our goal is to compare varying durations of postoperative immobilization after thumb CMC arthroplasty in a randomized trial design. Subjects will be randomized to treatment with non-removable thumb spica plaster postoperative splint immobilization for 2 weeks or non-removable thumb spica plaster splint transitioned to cast for a total of 6 weeks immobilization following base of thumb arthroplasty. Patient-reported outcome measures (PROs) and objective metrics will be tracked in the follow-up period.

Eligibility Criteria

Inclusion Criteria: * Age \>= 40 years old * Patients undergoing arthroplasty of the first CMC joint including: 1. Trapeziectomy with LRTI 2. Simple Trapeziectomy 3. Suspensionplasty (suture vs. APL) Exclusion Criteria: * Patients \< 40 years of age * Patients who have undergone prior surgical procedures on the thumb base * Patients with history of prior procedure at the base of thumb, or those with plan for concomitant carpal tunnel release or thumb metacarpophalangeal (MCP) arthrodesis, will be excluded. Concomitant carpal tunnel surgery may skew outcome surveys, and an arthrodesis procedure will warrant a longer length of immobilization following procedure. * Those undergoing implant arthroplasty * Patients with a diagnosis of inflammatory arthritis * Patients with diagnosis of hypermobility syndrome

Contact & Investigator

Central Contact

Andrew Straszewski, MD

✉ Andrew.Straszewski@uchospitals.edu

📞 773-834-3531

Principal Investigator

Jennifer Wolf, MD

PRINCIPAL INVESTIGATOR

University of Chicago

Frequently Asked Questions

Who can join the NCT04828954 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Thumb Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04828954 currently recruiting?

Yes, NCT04828954 is actively recruiting participants. Contact the research team at Andrew.Straszewski@uchospitals.edu for enrollment information.

Where is the NCT04828954 trial being conducted?

This trial is being conducted at Chicago, United States.

Who is sponsoring the NCT04828954 clinical trial?

NCT04828954 is sponsored by University of Chicago. The principal investigator is Jennifer Wolf, MD at University of Chicago. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology